The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...
In most years, Social Security cost of living adjustments increase to keep pace with inflation. The COLA for 2026 increased benefits by 2.8%, higher than the 2.5% increase in 2025. Some argue that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback